Litcius/Paper detail

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Aurore Perrot, Cyrille Hulin, Ariane Boumendil, Hamza Manjra, A. Lévêque, Carolyne Croizier, Arthur Dony, Mohamad Mohty, Murielle Roussel, Salomon Manier, Frédérique Orsini-Piocelle, Loïc Bauschert, Arthur Bobin, Laurent Frenzel, Laure Vincent, Claire Bréal, Jean Richard Eveillard, Thomas Gerome, Mourad Tiab, Émilie Chalayer, Rakiba Belkhir, Clara Mariette, Perrine Moyer, Thomas Chalopin, Brieuc Chérel, Lydia Montes, Arthur Coste, Reza Tabrizi, Lionel Karlin, Daniella Robu, Amandine Huguet, Stéphanie Harel, Philippe Moreau

2024Haematologica17 citationsDOIOpen Access PDF

Abstract

International audience

Topics & Concepts

Multiple myelomaRefractory (planetary science)Expanded accessMedicineOncologyInternal medicineBiologyAstrobiologyMultiple Myeloma Research and TreatmentsCancer Treatment and Pharmacology
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program | Litcius